Ergoresearch Inc. Grants Stock Options

MONTREAL, QUEBEC--(Marketwire - April 30, 2009) - The Board of directors of Ergoresearch Ltd. (“Ergoresearch ") (TSX VENTURE: ERG) has authorized the grant of stock options in favour of its officers and some key employees, in accordance with the company’s stock option plan. The options granted were allocated as follows:

 Mr Francois Tellier, Director, 200,000 options Mr Bryan Godbout, Director : 200 000 options Mr Michel Pierron, Director : 200 000 options Mrs Danielle Boucher, Director: 200 000 options Mrs Catherine Chamouton, Director: 200 000 options Mr Sylvain Boucher, President and CEO: 200 000 options 

As well, 400 000 were granted to key employees of the company or its subsidiaries. The exercise price of all of the options was fixed at $0.15 per share. Ergoresearch’s stock at the close of the market on April 29, 2009 was $0,15 / share. These options can be exercised within 10 years or at the latest on April 30, 2019, subject to the provisions of the stock option plan of Ergoresearch and TSX Venture Exchange policies.

A total of 2 000 000 stock options were initially made available in regard of the company’s stock option plan. The Board of Directors of Ergoresearch modified the company’s stock option plan to increase the number of stock options available for issuance at 5 000 000. The total amount of common shares issued is 59 606 275.

With the options granted as mentioned above, the total number of options currently granted to Directors and key employees is now at 1 785 000 stock options (at an average exercisable price of 0.15$ per share), thus leaving 3 215 000 stock options available to be granted.

Ergoresearch Ltd (www.ergorecherche.com) through its subsidiaries (www.cliniquedupiedequilibre.com) and (www.orthoconcept.com), is a leading general and foot orthotics manufacturer as well as being on the leading edge of durable medical equipment development in the orthopaedic industry. The Company owns patented technologies that confer competitive advantages in the industry and relies on its undeniable knowledge of consolidation in the healthcare industry.

THE TSX VENTURE EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.